291 related articles for article (PubMed ID: 27358266)
1. Conditions for Valid Empirical Estimates of Cancer Overdiagnosis in Randomized Trials and Population Studies.
Gulati R; Feuer EJ; Etzioni R
Am J Epidemiol; 2016 Jul; 184(2):140-7. PubMed ID: 27358266
[TBL] [Abstract][Full Text] [Related]
2. Quantifying Overdiagnosis in Cancer Screening: A Systematic Review to Evaluate the Methodology.
Ripping TM; Ten Haaf K; Verbeek ALM; van Ravesteyn NT; Broeders MJM
J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 29117353
[TBL] [Abstract][Full Text] [Related]
3. A mathematical model of case-ascertainment bias: Applied to case-control studies nested within a randomized screening trial.
Jansen RJ; Alexander BH; Hayes RB; Miller AB; Wacholder S; Church TR
PLoS One; 2018; 13(3):e0194608. PubMed ID: 29554151
[TBL] [Abstract][Full Text] [Related]
4. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.
Draisma G; Etzioni R; Tsodikov A; Mariotto A; Wever E; Gulati R; Feuer E; de Koning H
J Natl Cancer Inst; 2009 Mar; 101(6):374-83. PubMed ID: 19276453
[TBL] [Abstract][Full Text] [Related]
5. Overdiagnosis in the population-based organized breast cancer screening program estimated by a non-homogeneous multi-state model: a cohort study using individual data with long-term follow-up.
Wu WY; Törnberg S; Elfström KM; Liu X; Nyström L; Jonsson H
Breast Cancer Res; 2018 Dec; 20(1):153. PubMed ID: 30558679
[TBL] [Abstract][Full Text] [Related]
6. Breast, prostate, and thyroid cancer screening tests and overdiagnosis.
Jung M
Curr Probl Cancer; 2017; 41(1):71-79. PubMed ID: 28104314
[TBL] [Abstract][Full Text] [Related]
7. Obligate Overdiagnosis Due to Mammographic Screening: A Direct Estimate for U.S. Women.
Hendrick RE
Radiology; 2018 May; 287(2):391-397. PubMed ID: 29267146
[TBL] [Abstract][Full Text] [Related]
8. Estimation of overdiagnosis in breast cancer screening using a non-homogeneous multi-state model: A simulation study.
Wu WY; Nyström L; Jonsson H
J Med Screen; 2018 Dec; 25(4):183-190. PubMed ID: 29153013
[TBL] [Abstract][Full Text] [Related]
9. Extrapolation of pre-screening trends: Impact of assumptions on overdiagnosis estimates by mammographic screening.
Ripping TM; Verbeek AL; Ten Haaf K; van Ravesteyn NT; Broeders MJ
Cancer Epidemiol; 2016 Jun; 42():147-53. PubMed ID: 27153471
[TBL] [Abstract][Full Text] [Related]
10. Lifetime risk of prostate cancer overdiagnosis in Australia: quantifying the risk of overdiagnosis associated with prostate cancer screening in Australia using a novel lifetime risk approach.
Pathirana T; Hayen A; Doust J; Glasziou P; Bell K
BMJ Open; 2019 Mar; 9(3):e022457. PubMed ID: 30858156
[TBL] [Abstract][Full Text] [Related]
11. [Discrepancies and overdiagnosis in breast cancer organized screening. A "methodology" systematic review].
Gocko X; Leclerq M; Plotton C
Rev Epidemiol Sante Publique; 2018 Nov; 66(6):395-403. PubMed ID: 30316554
[TBL] [Abstract][Full Text] [Related]
12. Cancer-Specific Mortality, All-Cause Mortality, and Overdiagnosis in Lung Cancer Screening Trials: A Meta-Analysis.
Ebell MH; Bentivegna M; Hulme C
Ann Fam Med; 2020 Nov; 18(6):545-552. PubMed ID: 33168683
[TBL] [Abstract][Full Text] [Related]
13. Recognizing the Limitations of Cancer Overdiagnosis Studies: A First Step Towards Overcoming Them.
Etzioni R; Gulati R
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26582245
[TBL] [Abstract][Full Text] [Related]
14. Estimating the rate of overdiagnosis with prostate cancer screening: evidence from the Finnish component of the European Randomized Study of Screening for Prostate Cancer.
Walter SD; Hu J; Talala K; Tammela T; Taari K; Auvinen A
Cancer Causes Control; 2021 Nov; 32(11):1299-1313. PubMed ID: 34313874
[TBL] [Abstract][Full Text] [Related]
15. Missteps in Current Estimates of Cancer Overdiagnosis.
Lee CI; Etzioni R
Acad Radiol; 2017 Feb; 24(2):226-229. PubMed ID: 27894707
[TBL] [Abstract][Full Text] [Related]
16. Trends in lung cancer risk and screening eligibility affect overdiagnosis estimates.
Blom EF; Ten Haaf K; de Koning HJ
Lung Cancer; 2020 Jan; 139():200-206. PubMed ID: 31816564
[TBL] [Abstract][Full Text] [Related]
17. Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates.
Gulati R; Mariotto AB; Chen S; Gore JL; Etzioni R
J Clin Epidemiol; 2011 Dec; 64(12):1412-7. PubMed ID: 22032753
[TBL] [Abstract][Full Text] [Related]
18. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
19. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
[TBL] [Abstract][Full Text] [Related]
20. [Current aspects of prostate cancer screening].
Jalón Monzón A; Escaf Barmadah S; Viña Alonso LM; Jalón Monzón M
Semergen; 2017; 43(5):387-393. PubMed ID: 27562331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
